Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FR)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types
A Study of MORAb-202 in Participants With Selected Tumor Types
Sponsor:Eisai Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS8404
U.S. Government ID:NCT04300556
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of the first part of this study, the Dose Escalation part, is to study and identify the highest tolerable safe dose of MORAb-202. The purpose of the Expansion part is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness. This study will enroll patients with triple-negative breast cancer (TNBC), endometrial cancer (EC), non-small cell lung cancer (NSCLC, adenocarcinoma), primary peritoneal cancer or fallopian tube cancer, and ovarian cancer. If it is determined that you meet all of the study entry requirements, you will get an intravenous (IV) infusion of MORAb-202 once every 3 weeks (21 day cycle).

Do You Qualify?
Are you at least 18 years of age?YesNo
Have you been diagnosed with TNBC, EC, NSCLC, primary peritoneal cancer/fallopian tube cancer, or ovarian cancer?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162